Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 25Neoplasm Metastasis 5Breast Neoplasms 5Prostatic Neoplasms, Castration-Resistant 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostate Cancer Metastatic 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Carcinoma, Renal Cell 2Bulbo-Spinal Atrophy, X-Linked 2Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumours 1Small Cell Lung Carcinoma 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Preference 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Squamous Cell 1NSCLC Harboring NRG1 Fusion 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration Resistant Prostate Cancer 1Metastatic Castrate-Resistant Prostate Cancer 1

Interventions

enzalutamide 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Patient Preference × enzalutamide × Clear all
NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong

Phase 3 Terminated
74 enrolled
Genitourinary

Prostatic Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡